Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

20052,489 citationsJournal Articlebronze Open Access

Authors

Paul G. Richardson · Dana-Farber Cancer Institute

Pieter Sonneveld · Rotterdam University of Applied Sciences

Michael W. Schuster · NewYork–Presbyterian Hospital

David Irwin

Edward A. Stadtmauer · University of Pennsylvania

Thierry Façon · Hôpital Claude Huriez

Jean‐Luc Harousseau

Dina Ben‐Yehuda

Abstract

Bortezomib is superior to high-dose dexamethasone for the treatment of patients with multiple myeloma who have had a relapse after one to three previous therapies.

Topics & Keywords

Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 352, Issue 24, pp. 2487-2498

DOI: 10.1056/nejmoa043445

Field-Weighted Citation Impact: 83.24